|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q42278951
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000035.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q42278951
|
|
024
|
|
|
‡a
0000-0002-5813-6889
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q42278951
|
|
100
|
0 |
|
‡a
Antonio Rivero-Juarez
‡c
researcher
‡9
en
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Antonio Rivero-Juarez
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
|
|
670
|
|
|
‡a
Author's A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study)
|
|
670
|
|
|
‡a
Author's A model to predict the response to therapy against hepatitis C virus
|
|
670
|
|
|
‡a
Author's A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients
|
|
670
|
|
|
‡a
Author's A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.
|
|
670
|
|
|
‡a
Author's A regulatory polymorphism in HAVCR2 modulates susceptibility to HIV-1 infection
|
|
670
|
|
|
‡a
Author's Absence of Hepatitis E virus circulation in wild rabbits (Oryctolagus cuniculus) and Iberian hares (Lepus granatensis) in Mediterranean ecosystems in Spain
|
|
670
|
|
|
‡a
Author's Absence of occult Hepatitis E virus infection among HIV immunosuppressed patients
|
|
670
|
|
|
‡a
Author's Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
|
|
670
|
|
|
‡a
Author's Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection
|
|
670
|
|
|
‡a
Author's Association of low-density lipoprotein receptor genotypes with hepatitis C viral load
|
|
670
|
|
|
‡a
Author's Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
|
|
670
|
|
|
‡a
Author's Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients
|
|
670
|
|
|
‡a
Author's Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.
|
|
670
|
|
|
‡a
Author's Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
|
|
670
|
|
|
‡a
Author's Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
|
|
670
|
|
|
‡a
Author's Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
|
|
670
|
|
|
‡a
Author's Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients
|
|
670
|
|
|
‡a
Author's Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin
|
|
670
|
|
|
‡a
Author's Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users.
|
|
670
|
|
|
‡a
Author's Current views on interferon therapy for HIV.
|
|
670
|
|
|
‡a
Author's Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection
|
|
670
|
|
|
‡a
Author's Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients
|
|
670
|
|
|
‡a
Author's Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
|
|
670
|
|
|
‡a
Author's Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.
|
|
670
|
|
|
‡a
Author's Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
|
|
670
|
|
|
‡a
Author's Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain
|
|
670
|
|
|
‡a
Author's Enterocytozoon bieneusi (Microsporidia): identification of novel genotypes and evidence of transm ission between sympatric wild boars (Sus scrofa ferus) and Iberian pigs (Sus scrofa domesticus) in Southern Spain
|
|
670
|
|
|
‡a
Author's Evaluation of a non-invasive screening approach to determine hepatitis E virus status of pig farms
|
|
670
|
|
|
‡a
Author's Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection.
|
|
670
|
|
|
‡a
Author's Familial Hepatitis E Outbreak Linked to Wild Boar Meat Consumption
|
|
670
|
|
|
‡a
Author's Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.
|
|
670
|
|
|
‡a
Author's Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability
|
|
670
|
|
|
‡a
Author's Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection
|
|
670
|
|
|
‡a
Author's Global molecular diversity of Hepatitis E virus in wild boar and domestic pig
|
|
670
|
|
|
‡a
Author's HCV genotype 3: a wolf in sheep's clothing.
|
|
670
|
|
|
‡a
Author's HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
|
|
670
|
|
|
‡a
Author's Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study
|
|
670
|
|
|
‡a
Author's Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
|
|
670
|
|
|
‡a
Author's Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
|
|
670
|
|
|
‡a
Author's Hepatitis E Virus (HEV) Infection in Anti-HEV Immunoglobulin G-Carrying Patients After Successful Hepatitis C Virus Treatment: Reactivation or Reinfection?
|
|
670
|
|
|
‡a
Author's Hepatitis E virus in Spanish donors and the necessity for screening
|
|
670
|
|
|
‡a
Author's Hepatitis E virus infection in equines in Spain
|
|
670
|
|
|
‡a
Author's High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
|
|
670
|
|
|
‡a
Author's High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients
|
|
670
|
|
|
‡a
Author's High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease
|
|
670
|
|
|
‡a
Author's HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
|
|
670
|
|
|
‡a
Author's HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.
|
|
670
|
|
|
‡a
Author's HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients.
|
|
670
|
|
|
‡a
Author's IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.
|
|
670
|
|
|
‡a
Author's IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians
|
|
670
|
|
|
‡a
Author's Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals
|
|
670
|
|
|
‡a
Author's Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin
|
|
670
|
|
|
‡a
Author's Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection
|
|
670
|
|
|
‡a
Author's Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
|
|
670
|
|
|
‡a
Author's Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients
|
|
670
|
|
|
‡a
Author's Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.
|
|
670
|
|
|
‡a
Author's Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain
|
|
670
|
|
|
‡a
Author's Influence of the Combination of Low-Density Lipoprotein Receptor and Interleukin 28B Genotypes on Lipid Plasma Levels in HIV/Hepatitis C-Coinfected Patients
|
|
670
|
|
|
‡a
Author's Isolation of Hepatitis E Virus From Breast Milk During Acute Infection
|
|
670
|
|
|
‡a
Author's KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy
|
|
670
|
|
|
‡a
Author's LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
|
|
670
|
|
|
‡a
Author's Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients
|
|
670
|
|
|
‡a
Author's Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis.
|
|
670
|
|
|
‡a
Author's Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis
|
|
670
|
|
|
‡a
Author's Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients
|
|
670
|
|
|
‡a
Author's Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis
|
|
670
|
|
|
‡a
Author's Liver stiffness using transient elastography is applicable to canines for hepatic disease models.
|
|
670
|
|
|
‡a
Author's Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort
|
|
670
|
|
|
‡a
Author's Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance
|
|
670
|
|
|
‡a
Author's Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.
|
|
670
|
|
|
‡a
Author's Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
|
|
670
|
|
|
‡a
Author's Monitoring of Schmallenberg virus in Spanish wild artiodactyls, 2006-2015.
|
|
670
|
|
|
‡a
Author's Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients
|
|
670
|
|
|
‡a
Author's Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
|
|
670
|
|
|
‡a
Author's Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
|
|
670
|
|
|
‡a
Author's Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar.
|
|
670
|
|
|
‡a
Author's Persistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune response
|
|
670
|
|
|
‡a
Author's Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.
|
|
670
|
|
|
‡a
Author's Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
|
|
670
|
|
|
‡a
Author's Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.
|
|
670
|
|
|
‡a
Author's Prevalence of hepatitis E virus infection in wild boars from Spain: a possible seasonal pattern?
|
|
670
|
|
|
‡a
Author's Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C.
|
|
670
|
|
|
‡a
Author's Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.
|
|
670
|
|
|
‡a
Author's Re-emergence of bluetongue virus serotype 4 in Iberian ibex (Capra pyrenaica) and sympatric livestock in Spain, 2018-2019
|
|
670
|
|
|
‡a
Author's Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
|
|
670
|
|
|
‡a
Author's Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy
|
|
670
|
|
|
‡a
Author's Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
|
|
670
|
|
|
‡a
Author's Response to the Letter to the Editor concerning "Absence of hepatitis E virus circulation in wild rabbits (Oryctolagus cuniculus) and Iberian hares (Lepus granatensis) in Mediterranean ecosystems in Spain" by Caballero-Gómez et al. (Transbound Emerg
|
|
670
|
|
|
‡a
Author's Role of Hepatitis E Virus Infection in Acute-on-Chronic Liver Failure
|
|
670
|
|
|
‡a
Author's Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: A prospective longitudinal study.
|
|
670
|
|
|
‡a
Author's Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
|
|
670
|
|
|
‡a
Author's Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.
|
|
670
|
|
|
‡a
Author's Survey for Hepatitis E virus infection in non-human primates in zoos in Spain
|
|
670
|
|
|
‡a
Author's Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
|
|
670
|
|
|
‡a
Author's Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
|
|
670
|
|
|
‡a
Author's Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.
|
|
670
|
|
|
‡a
Author's The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
|
|
670
|
|
|
‡a
Author's The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
|
|
670
|
|
|
‡a
Author's The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
|
|
670
|
|
|
‡a
Author's Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
|
|
670
|
|
|
‡a
Author's Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.
|
|
909
|
|
|
‡a
(orcid) 0000000258136889
‡9
1
|
|
919
|
|
|
‡a
sustainedvirologicalresponsewithsofosbuvirandledipasvirforhepatitis100virusgenotype5
‡A
Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.
‡9
1
|
|
919
|
|
|
‡a
sustainedvirologicalresponsetopegylatedinterferonplusribavirinleadstonormalizationofliverstiffnessinhepatitis100virusinfectedpatients
‡A
Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
‡9
1
|
|
919
|
|
|
‡a
sustainedvirologicalresponseinhivhcvcoinfectedpatientstreatedwithpegylatedinterferonribavirincanbepredictedfromtheoverallrateofviralloaddeclineoverthe14weeksoftherapy
‡A
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
‡9
1
|
|
919
|
|
|
‡a
surveyforhepatitisevirusinfectioninnonhumanprimatesinzoosinspain
‡A
Survey for Hepatitis E virus infection in non-human primates in zoos in Spain
‡9
1
|
|
919
|
|
|
‡a
spontaneousclearanceofchronichepatitis100israreinhivinfectedpatientsaftereffectiveuseofcombinationantiretroviraltherapy
‡A
Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.
‡9
1
|
|
919
|
|
|
‡a
shortcommunicationatazanavirbasedtherapyisassociatedwithhigherhepatitis100viralloadinhivtype1infectedsubjectswithuntreatedhepatitis100
‡A
Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
‡9
1
|
|
919
|
|
|
‡a
ruralhabitatasriskfactorforhepatitisevirusseroconversioninhivinfectedpatientsaprospectivelongitudinalstudy
‡A
Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: A prospective longitudinal study.
‡9
1
|
|
919
|
|
|
‡a
roleofhepatitisevirusinfectioninacuteonchronicliverfailure
‡A
Role of Hepatitis E Virus Infection in Acute-on-Chronic Liver Failure
‡9
1
|
|
919
|
|
|
‡a
responsetothelettertotheeditorconcerningabsenceofhepatitiseviruscirculationinwildrabbitsoryctolaguscuniculusandiberianhareslepusgranatensisinmediterraneanecosystemsinspainbycaballerogomezetaltransboundemerg
‡A
Response to the Letter to the Editor concerning "Absence of hepatitis E virus circulation in wild rabbits (Oryctolagus cuniculus) and Iberian hares (Lepus granatensis) in Mediterranean ecosystems in Spain" by Caballero-Gómez et al. (Transbound Emerg
‡9
1
|
|
919
|
|
|
‡a
responsetopegylatedinterferonplusribavirinamonghivhepatitis100viruscoinfectedpatientswithcompensatedlivercirrhosis
‡A
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
‡9
1
|
|
919
|
|
|
‡a
responsetodirectactingantiviraltherapyamongongoingdrugusersandpeoplereceivingopioidsubstitutiontherapy
‡A
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy
‡9
1
|
|
919
|
|
|
‡a
reallifeexperiencewithsorafenibforthetreatmentofhepatocellularcarcinomainhivinfectedpatients
‡A
Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
‡9
1
|
|
919
|
|
|
‡a
reemergenceofbluetonguevirusserotype4iniberianibexcaprapyrenaicaandsympatriclivestockinspain2018
‡A
Re-emergence of bluetongue virus serotype 4 in Iberian ibex (Capra pyrenaica) and sympatric livestock in Spain, 2018-2019
‡9
1
|
|
919
|
|
|
‡a
progressionofliverstiffnesspredictsclinicaleventsinhivhcvcoinfectedpatientswithcompensatedcirrhosis
‡A
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.
‡9
1
|
|
919
|
|
|
‡a
prognosticvalueoftransientelastographyinhumanimmunodeficiencyvirusinfectedpatientswithchronichepatitis100
‡A
Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C.
‡9
1
|
|
919
|
|
|
‡a
prevalenceofhepatitisevirusinfectioninwildboarsfromspainapossibleseasonalpattern
‡A
Prevalence of hepatitis E virus infection in wild boars from Spain: a possible seasonal pattern?
‡9
1
|
|
919
|
|
|
‡a
pharmacokineticsandpharmacodynamicsofsofosbuvirandledipasvirforthetreatmentofhepatitis100
‡A
Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.
‡9
1
|
|
919
|
|
|
‡a
pharmacokineticdrugevaluationofvelpatasvirplussofosbuvirforthetreatmentofhepatitis100virusinfection
‡A
Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
‡9
1
|
|
919
|
|
|
‡a
pharmacokineticandpharmacodynamicevaluationoftelaprevirforthetreatmentofhepatitis100
‡A
Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.
‡9
1
|
|
919
|
|
|
‡a
persistenceofpathologicaldistributionofnkcellsinhivinfectedpatientswithprolongeduseofhaartandasustainedimmuneresponse
‡A
Persistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune response
‡9
1
|
|
919
|
|
|
‡a
persistenceofhepatitisevirusintheliverofnonviremicnaturallyinfectedwildboar
‡A
Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar.
‡9
1
|
|
919
|
|
|
‡a
pegylatedinterferonplusribavirinissuboptimalinil28b200carrierswithoutrapidresponse
‡A
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
‡9
1
|
|
919
|
|
|
‡a
parenteraldruguseasthemainbarriertohepatitis100treatmentuptakeinhivinfectedpatients
‡A
Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
‡9
1
|
|
919
|
|
|
‡a
naturalkillerkir3ds1iscloselyassociatedwithhcvviralclearanceandsustainedvirologicalresponseinhivhcvpatients
‡A
Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients
‡9
1
|
|
919
|
|
|
‡a
monitoringofschmallenbergvirusinspanishwildartiodactyls2006
‡A
Monitoring of Schmallenberg virus in Spanish wild artiodactyls, 2006-2015.
‡9
1
|
|
919
|
|
|
‡a
lowefficacyofpegylatedinterferonplusribavirinplusnitazoxanideforhcvgenotype4andhivcoinfection
‡A
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
‡9
1
|
|
919
|
|
|
‡a
lowdensitylipoproteinreceptorgenotypingenhancesthepredictivevalueofil28bgenotypeinhivhepatitis100viruscoinfectedpatients
‡A
Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.
‡9
1
|
|
919
|
|
|
‡a
longitudinalevaluationofhepatitis100viralpersistenceinhivinfectedpatientswithspontaneoushepatitis100clearance
‡A
Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance
‡9
1
|
|
919
|
|
|
‡a
livertoxicityofcurrentantiretroviralregimensinhivinfectedpatientswithchronicviralhepatitisinareallifesettingthehepavirseghepcohort
‡A
Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort
‡9
1
|
|
919
|
|
|
‡a
liverstiffnessusingtransientelastographyisapplicabletocaninesforhepaticdiseasemodels
‡A
Liver stiffness using transient elastography is applicable to canines for hepatic disease models.
‡9
1
|
|
919
|
|
|
‡a
liverstiffnesspredictsvaricealbleedinginhivhcvcoinfectedpatientswithcompensatedcirrhosis
‡A
Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis
‡9
1
|
|
919
|
|
|
‡a
liverstiffnesspredictstheresponsetodirectactingantiviralbasedtherapyagainstchronichepatitis100incirrhoticpatients
‡A
Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients
‡9
1
|
|
919
|
|
|
‡a
liverstiffnesspredictsclinicaloutcomeinhumanimmunodeficiencyvirushepatitis100viruscoinfectedpatientswithcompensatedlivercirrhosis
‡A
Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis
‡9
1
|
|
919
|
|
|
‡a
liverstiffnesscorrelateswithchildpughturcotteandmeldscoresinhivhepatitis100viruscoinfectedpatientswithcirrhosis
‡A
Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis.
‡9
1
|
|
919
|
|
|
‡a
liverfibrosishostgeneticandhepatitis100virusrelatedparametersaspredictivefactorsofresponsetotherapyagainsthepatitis100virusinhivhcvcoinfectedpatients
‡A
Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients
‡9
1
|
|
919
|
|
|
‡a
ldlrgenotypemodifiestheimpactofil28bonhcvviralkineticsafterthe1weeksoftreatmentwithpegifnrbvinhivhcvpatients
‡A
LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
‡9
1
|
|
919
|
|
|
‡a
kir2ds2aspredictorofthrombocytopeniasecondarytopegylatedinterferonalphatherapy
‡A
KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy
‡9
1
|
|
919
|
|
|
‡a
isolationofhepatitisevirusfrombreastmilkduringacuteinfection
‡A
Isolation of Hepatitis E Virus From Breast Milk During Acute Infection
‡9
1
|
|
919
|
|
|
‡a
influenceofthecombinationoflowdensitylipoproteinreceptorandinterleukin28bgenotypesonlipidplasmalevelsinhivhepatitis100coinfectedpatients
‡A
Influence of the Combination of Low-Density Lipoprotein Receptor and Interleukin 28B Genotypes on Lipid Plasma Levels in HIV/Hepatitis C-Coinfected Patients
‡9
1
|
|
919
|
|
|
‡a
incidenceofrecentlyacquiredhepatitis100virusinfectionamonghivinfectedpatientsinsouthernspain
‡A
Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain
‡9
1
|
|
919
|
|
|
‡a
incidenceofliverdamageofuncertainorigininhivpatientsnotcoinfectedwithhcvhbv
‡A
Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.
‡9
1
|
|
919
|
|
|
‡a
incidenceandnaturalhistoryofhepatitiseviruscoinfectionamonghivinfectedpatients
‡A
Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients
‡9
1
|
|
919
|
|
|
‡a
impactofuniversalaccesstohepatitis100therapyonhivinfectedpatientsimplementationofthespanishnationalhepatitis100strategy
‡A
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
‡9
1
|
|
919
|
|
|
‡a
impactofil28bgenotypeon1weekresponsetotelaprevirbasedtherapyinhivhcvcoinfection
‡A
Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection
‡9
1
|
|
919
|
|
|
‡a
impactofhivinfectiononsustainedvirologicalresponsetotreatmentagainsthepatitis100viruswithpegylatedinterferonplusribavirin
‡A
Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin
‡9
1
|
|
919
|
|
|
‡a
impactofgeneticpolymorphismsassociatedwithnonalcoholicfattyliverdiseaseonhivinfectedindividuals
‡A
Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals
‡9
1
|
|
919
|
|
|
‡a
ifnl4ss469415590variantshowssimilarperformancetors12979860aspredictorofresponsetotreatmentagainsthepatitis100virusgenotype1or4incaucasians
‡A
IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians
‡9
1
|
|
919
|
|
|
‡a
ifnl4rs368234815polymorphismisassociatedwithinnateresistancetohiv1infection
‡A
IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.
‡9
1
|
|
919
|
|
|
‡a
hlab18asriskfactorofliverfibrosisprogressioninhivhcvtreatmentexperiencedpatients
‡A
HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients.
‡9
1
|
|
919
|
|
|
‡a
hlab18asariskfactorofshorttermprogressiontosevereliverfibrosisinhivhcvcoinfectedpatientswithabsentorminimalfibrosisimplicationsfortimingoftherapy
‡A
HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.
‡9
1
|
|
919
|
|
|
‡a
hivcoinfectedpatientsrespondworsetodirectactingantiviralbasedtherapyagainstchronichepatitis100inreallifethanhcvmonoinfectedindividualsaprospectivecohortstudy
‡A
HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
‡9
1
|
|
919
|
|
|
‡a
highprevalenceofantibodiesagainsthepatitisevirusinhivinfectedpatientswithunexplainedliverdisease
‡A
High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease
‡9
1
|
|
919
|
|
|
‡a
highhepatitisevirusseroprevalencewithabsenceofchronicinfectioninhivinfectedpatients
‡A
High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients
‡9
1
|
|
919
|
|
|
‡a
highefficacyofresistanceguidedretreatmentofhcvpatientsfailingns5ainhibitorsintherealworld
‡A
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
‡9
1
|
|
919
|
|
|
‡a
hepatitisevirusinfectioninequinesinspain
‡A
Hepatitis E virus infection in equines in Spain
‡9
1
|
|
919
|
|
|
‡a
hepatitisevirusinspanishdonorsandthenecessityforscreening
‡A
Hepatitis E virus in Spanish donors and the necessity for screening
‡9
1
|
|
919
|
|
|
‡a
hepatitisevirushevinfectioninantihevimmunoglobulingcarryingpatientsaftersuccessfulhepatitis100virustreatmentreactivationorreinfection
‡A
Hepatitis E Virus (HEV) Infection in Anti-HEV Immunoglobulin G-Carrying Patients After Successful Hepatitis C Virus Treatment: Reactivation or Reinfection?
‡9
1
|
|
919
|
|
|
‡a
hepatitis100virusgenotype4respondsbettertopegylatedinterferonwithribavirinthangenotype1inhivinfectedpatients
‡A
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
‡9
1
|
|
919
|
|
|
‡a
hepaticsafetyofrpvftctdfsingletabletregimeninhivhcvcoinfectedpatientspreliminaryresultsofthehepaticstudy
‡A
Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
‡9
1
|
|
919
|
|
|
‡a
hepaticsafetyofrilpivirineemtricitabinetenofovirdisoproxilfumaratefixeddosesingletabletregimeninhivinfectedpatientswithactivehepatitis100virusinfectionthehepaticstudy
‡A
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study
‡9
1
|
|
919
|
|
|
‡a
hcvviraldeclineatweek2ofpegifnalpha2arbvtherapyasapredictivetoolfortailoringtreatmentinhivhcvgenotype1coinfectedpatients
‡A
HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
‡9
1
|
|
919
|
|
|
‡a
hcvgenotype3awolfinsheepsclothing
‡A
HCV genotype 3: a wolf in sheep's clothing.
‡9
1
|
|
919
|
|
|
‡a
globalmoleculardiversityofhepatitisevirusinwildboaranddomesticpig
‡A
Global molecular diversity of Hepatitis E virus in wild boar and domestic pig
‡9
1
|
|
919
|
|
|
‡a
geneticmarkersoflipidmetabolismgenesassociatedwithlowsusceptibilitytohcvinfection
‡A
Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection
‡9
1
|
|
919
|
|
|
‡a
geneticassociationsofthevitamin500andantiviralpathwayswithnaturalresistancetohiv1infectionareinfluencedbyinterpopulationvariability
‡A
Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability
‡9
1
|
|
919
|
|
|
‡a
fatmassandobesityassociatedgenevariationsarerelatedtofattyliverdiseaseinhivinfectedpatients
‡A
Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients.
‡9
1
|
|
919
|
|
|
‡a
familialhepatitiseoutbreaklinkedtowildboarmeatconsumption
‡A
Familial Hepatitis E Outbreak Linked to Wild Boar Meat Consumption
‡9
1
|
|
919
|
|
|
‡a
evolutionaryanalysisidentifiesanmx2haplotypeassociatedwithnaturalresistancetohiv1infection
‡A
Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection.
‡9
1
|
|
919
|
|
|
‡a
evaluationofanoninvasivescreeningapproachtodeterminehepatitisevirusstatusofpigfarms
‡A
Evaluation of a non-invasive screening approach to determine hepatitis E virus status of pig farms
‡9
1
|
|
919
|
|
|
‡a
enterocytozoonbieneusimicrosporidiaidentificationofnovelgenotypesandevidenceoftransmissionbetweensympatricwildboarssusscrofaferusandiberianpigssusscrofadomesticusinsouthernspain
‡A
Enterocytozoon bieneusi (Microsporidia): identification of novel genotypes and evidence of transm ission between sympatric wild boars (Sus scrofa ferus) and Iberian pigs (Sus scrofa domesticus) in Southern Spain
‡9
1
|
|
919
|
|
|
‡a
emergentsubtypeofhepatitisevirusgenotype3inwildboarinspain
‡A
Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain
‡9
1
|
|
919
|
|
|
‡a
efficacyofandriskofbleedingduringpegylatedinterferonplusribavirintreatmentinhivhcvcoinfectedpatientswithpretreatmentthrombocytopenia
‡A
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
‡9
1
|
|
919
|
|
|
‡a
effectsofthegeneticpatterndefinedbylowdensitylipoproteinreceptorandil28bgenotypesontheoutcomeofhepatitis100virusinfection
‡A
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.
‡9
1
|
|
919
|
|
|
‡a
dimensionofchronichepatitis100virusinhivinfectedpatientsintheinterferonfreeeraanoverviewfromsouthspain
‡A
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
‡9
1
|
|
919
|
|
|
‡a
differencesinhcvviraldeclinebetweenlowandstandarddosepegylatedinterferonalpha2awithribavirininhivhcvgenotype3patients
‡A
Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients
‡9
1
|
|
919
|
|
|
‡a
detectionofhepatitisevirusrnainsalivafordiagnosisofacuteinfection
‡A
Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection
‡9
1
|
|
919
|
|
|
‡a
currentviewsoninterferontherapyforhiv
‡A
Current views on interferon therapy for HIV.
‡9
1
|
|
919
|
|
|
‡a
commonhaplotypesincd209promoterandsusceptibilitytohiv1infectioninintravenousdrugusers
‡A
Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users.
‡9
1
|
|
919
|
|
|
‡a
changesinliverstiffnessinpatientswithchronichepatitis100withandwithouthivcoinfectiontreatedwithpegylatedinterferonplusribavirin
‡A
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin
‡9
1
|
|
919
|
|
|
‡a
changesinliversteatosisevaluatedbytransientelastographywiththecontrolledattenuationparameterinhivinfectedpatients
‡A
Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients
‡9
1
|
|
919
|
|
|
‡a
changesinliversteatosisafterswitchingfromefavirenztoraltegraviramonghumanimmunodeficiencyvirusinfectedpatientswithnonalcoholicfattyliverdisease
‡A
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
‡9
1
|
|
919
|
|
|
‡a
boceprevirortelaprevirbasedtripletherapyagainstchronichepatitis100inhivcoinfectionreallifesafetyandefficacy
‡A
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
‡9
1
|
|
919
|
|
|
‡a
benefitsfromsustainedvirologicresponsetopegylatedinterferonplusribavirininhivhepatitis100viruscoinfectedpatientswithcompensatedcirrhosis
‡A
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
‡9
1
|
|
919
|
|
|
‡a
baselineriskfactorsforrelapseinhivhcvcoinfectedpatientstreatedwithpegifnrbv
‡A
Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.
‡9
1
|
|
919
|
|
|
‡a
bacterialtranslocationandclinicalprogressionofhcvrelatedcirrhosisinhivinfectedpatients
‡A
Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients
‡9
1
|
|
919
|
|
|
‡a
atazanavirbasedtherapywithpegylatedinterferonandribavirinforpatientswithhepatitis100andhiv
‡A
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
‡9
1
|
|
919
|
|
|
‡a
associationoflowdensitylipoproteinreceptorgenotypeswithhepatitis100viralload
‡A
Association of low-density lipoprotein receptor genotypes with hepatitis C viral load
‡9
1
|
|
919
|
|
|
‡a
associationofcomplementreceptor2polymorphismswithinnateresistancetohiv1infection
‡A
Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection
‡9
1
|
|
919
|
|
|
‡a
associationbetweentheil28bgenotypeandhepatitis100viralkineticsintheearlydaysoftreatmentwithpegylatedinterferonplusribavirininhivhcvcoinfectedpatientswithgenotype1or4
‡A
Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
‡9
1
|
|
919
|
|
|
‡a
absenceofocculthepatitisevirusinfectionamonghivimmunosuppressedpatients
‡A
Absence of occult Hepatitis E virus infection among HIV immunosuppressed patients
‡9
1
|
|
919
|
|
|
‡a
absenceofhepatitiseviruscirculationinwildrabbitsoryctolaguscuniculusandiberianhareslepusgranatensisinmediterraneanecosystemsinspain
‡A
Absence of Hepatitis E virus circulation in wild rabbits (Oryctolagus cuniculus) and Iberian hares (Lepus granatensis) in Mediterranean ecosystems in Spain
‡9
1
|
|
919
|
|
|
‡a
regulatorypolymorphisminhavcr2modulatessusceptibilitytohiv1infection
‡A
A regulatory polymorphism in HAVCR2 modulates susceptibility to HIV-1 infection
‡9
1
|
|
919
|
|
|
‡a
polymorphismlinkedtorrasscaf1irf3andbcl2l12genesisassociatedwithcirrhosisinhepatitis100viruscarriers
‡A
A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.
‡9
1
|
|
919
|
|
|
‡a
modeltopredicttheresponsetotherapyagainsthepatitis100virushcvincludinglowdensitylipoproteinreceptorgenotypeinhivhcvcoinfectedpatients
‡A
A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients
‡9
1
|
|
919
|
|
|
‡a
modeltopredicttheresponsetotherapyagainsthepatitis100virus
‡A
A model to predict the response to therapy against hepatitis C virus
‡9
1
|
|
919
|
|
|
‡a
genomewideassociationstudyonlowsusceptibilitytohepatitis100virusinfectiongehep012study
‡A
A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study)
‡9
1
|
|
919
|
|
|
‡a
24weektreatmentstrategywithpegylatedinterferonribavirininhivhepatitis100virusgenotype3coinfectedpatientswhoachievedarapidvirologicresponseresultsinahighsustainedvirologicresponserate
‡A
A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
‡9
1
|
|
919
|
|
|
‡a
variationsatmultiplegenesimproveinterleukin28bgenotypepredictivecapacityforresponsetotherapyagainsthepatitis100infection
‡A
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.
‡9
1
|
|
919
|
|
|
‡a
12weekposttreatmentfollowuppredictssustainedvirologicalresponsetopegylatedinterferonandribavirintherapyinhivhepatitis100viruscoinfectedpatients
‡A
Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
‡9
1
|
|
919
|
|
|
‡a
riskofhepatocellularcarcinomaaftersustainedvirologicalresponseinpatientstreatedwiththenewdirectactingantiviraldrugsshouldwebeworryaboutit
‡A
The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
‡9
1
|
|
919
|
|
|
‡a
pnpla3geneticvariantrs738409influencestheprogressiontocirrhosisinhivhepatitis100viruscoinfectedpatients
‡A
The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
‡9
1
|
|
919
|
|
|
‡a
il28beffectonhepatitis100viruskineticsamonghivpatientsafterthe1weeksofpegylatedinterferonribavirintreatmentvariesaccordingtohepatitis100virus1subtype
‡A
The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
‡9
1
|
|
943
|
|
|
‡a
201x
‡A
2019
‡9
2
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
BNE|XX837371
|
|
996
|
|
|
‡2
LC|n 80070881
|
|
996
|
|
|
‡2
ISNI|0000000059411243
|
|
996
|
|
|
‡2
J9U|987007308811805171
|
|
996
|
|
|
‡2
DNB|132523930
|
|
996
|
|
|
‡2
BNF|14468103
|
|
996
|
|
|
‡2
LC|ns2012005660
|
|
996
|
|
|
‡2
LC|no2013056083
|
|
996
|
|
|
‡2
BNC|981058513271406706
|
|
996
|
|
|
‡2
BNC|981060405994306706
|
|
996
|
|
|
‡2
ISNI|0000000061062062
|
|
996
|
|
|
‡2
LC|ns2021002545
|
|
996
|
|
|
‡2
BNC|981058609856506706
|
|
996
|
|
|
‡2
BNE|XX1596078
|
|
996
|
|
|
‡2
BNE|XX838294
|
|
996
|
|
|
‡2
SUDOC|157747891
|
|
996
|
|
|
‡2
BNE|XX935784
|
|
996
|
|
|
‡2
BNE|XX1753560
|
|
996
|
|
|
‡2
BNE|XX6326190
|
|
996
|
|
|
‡2
LC|ns2014003927
|
|
996
|
|
|
‡2
BNE|XX1353593
|
|
996
|
|
|
‡2
BNCHL|10000000000000000871448
|
|
996
|
|
|
‡2
BNE|XX1033726
|
|
996
|
|
|
‡2
SUDOC|155593366
|
|
996
|
|
|
‡2
BNE|XX943048
|
|
996
|
|
|
‡2
DNB|1157230040
|
|
996
|
|
|
‡2
RERO|A003436148
|
|
996
|
|
|
‡2
BNE|XX5173645
|
|
996
|
|
|
‡2
BNE|XX1047137
|
|
996
|
|
|
‡2
BNE|XX1007362
|
|
996
|
|
|
‡2
BNE|XX876416
|
|
996
|
|
|
‡2
DNB|1057141542
|
|
996
|
|
|
‡2
ISNI|0000000409050485
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
